243 related articles for article (PubMed ID: 32374397)
1. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model.
Binka M; Janjua NZ; Grebely J; Estes C; Schanzer D; Kwon JA; Shoukry NH; Kwong JC; Razavi H; Feld JJ; Krajden M
JAMA Netw Open; 2020 May; 3(5):e204192. PubMed ID: 32374397
[TBL] [Abstract][Full Text] [Related]
2. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
3. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
[TBL] [Abstract][Full Text] [Related]
5. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
[TBL] [Abstract][Full Text] [Related]
6. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
7. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.
Chhatwal J; Chen Q; Wang X; Ayer T; Zhuo Y; Janjua NZ; Kanwal F
JAMA Netw Open; 2019 May; 2(5):e193613. PubMed ID: 31074817
[TBL] [Abstract][Full Text] [Related]
9. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
[TBL] [Abstract][Full Text] [Related]
10. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
Blake A; Smith JE
JAMA Netw Open; 2021 Aug; 4(8):e2119092. PubMed ID: 34342652
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
12. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
[TBL] [Abstract][Full Text] [Related]
13. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030.
van Dijk M; Brakenhoff SM; Isfordink CJ; Cheng WH; Blokzijl H; Boland G; Dofferhoff ASM; van Hoek B; van Nieuwkoop C; Sonneveld MJ; van der Valk M; Drenth JPH; de Knegt RJ
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640576
[TBL] [Abstract][Full Text] [Related]
14. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
15. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
[TBL] [Abstract][Full Text] [Related]
16. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
[TBL] [Abstract][Full Text] [Related]
17. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
20. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
